Sanofi (NASDAQ:SNY) Stock Holdings Reduced by Motco

Key Points

• Motco reduced its stake in Sanofi by 13.0% in the first quarter, selling 10,461 shares and ending up with 70,108 shares valued at approximately $3.89 million.
• Institutional investors showed mixed activity, with HB Wealth Management increasing its stake in Sanofi by 114.5%, while several others, including Cetera Investment Advisers and Avantax Advisory Services, also raised their stakes significantly.
• Sanofi's stock has a current average rating of "Buy" with a consensus target price of $61.50, according to multiple equities research analysts.

Motco lessened its stake in Sanofi (NASDAQ:SNY - Free Report) by 13.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,108 shares of the company's stock after selling 10,461 shares during the period. Motco's holdings in Sanofi were worth $3,888,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Golden State Wealth Management LLC raised its holdings in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares in the last quarter. Bessemer Group Inc. boosted its holdings in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after buying an additional 242 shares during the last quarter. UMB Bank n.a. raised its stake in Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after acquiring an additional 264 shares during the period. Wayfinding Financial LLC bought a new stake in shares of Sanofi during the first quarter valued at approximately $63,000. Finally, Tsfg LLC increased its position in Sanofi by 1,107.0% in the first quarter. Tsfg LLC now owns 1,207 shares of the company's stock worth $67,000 after purchasing an additional 1,107 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Down 0.4%

NASDAQ SNY traded down $0.18 during mid-day trading on Wednesday, reaching $49.18. 736,200 shares of the company's stock traded hands, compared to its average volume of 2,512,963. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company has a fifty day simple moving average of $49.42 and a 200-day simple moving average of $52.13. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The company has a market cap of $120.60 billion, a price-to-earnings ratio of 17.58, a P/E/G ratio of 1.13 and a beta of 0.48.

Analyst Ratings Changes

SNY has been the subject of a number of recent analyst reports. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research note on Monday, June 2nd. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. BNP Paribas assumed coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Barclays restated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.